Related Experiment Video
Updated: Jun 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation
Katherine A Lyseng-Williamson1
1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
Abstract:
Oral fixed-dose niacin extended release/simvastatin is associated with clinically relevant improvements in plasma lipid profiles, including lowering of non-high-density lipoprotein cholesterol levels, relative to simvastatin monotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis IV: Nursing Management
Atherosclerosis III: Management
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
